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Background: Patients with liver cirrhosis are not only at increased risk of bleeding, but also 
may suffer from complications such as venous thromboembolism (VTE). Data are limited 
about the relative frequency, clinical course, management, and outcomes of VTE in these 
patients.  
Methods: We used the data from RIETE, a prospective multicenter international registry of 
consecutive patients with objectively-confirmed VTE (deep vein thrombosis [DVT], 
pulmonary embolism [PE], or both) and focused on those with biopsy-confirmed cirrhosis. 
We compared the outcomes in VTE patients with and without cirrhosis. Main outcome 
measures included 90-day PE-related mortality, all-cause mortality, recurrent VTE, and 
major bleeding. 
Results: Among 43,611 eligible patients with acute VTE, 187 (0.43%) had cirrhosis. Of 
these, 184 (98.4%) received anticoagulation (median duration: 109 [IQR: 43-201] days; 
most common agent and daily dose: enoxaparin 177 [IQR: 138-200] IU/Kg/day). During 
the course of anticoagulation, patients with cirrhosis had a higher-rate of 30-day fatal 
bleeding (2.1% versus 0.16%; P<0.001), and all-cause mortality (11% versus 3.4%; 
P<0.001), but similar rates of fatal PE (0.53% versus 0.46%, P=0.57), compared with VTE 
patients without cirrhosis. Ninety-day and 1-year outcomes were consistently worse in VTE 
patients with cirrhosis. The 1-year cumulative incidence of VTE recurrence was 8.5% in 
patients with cirrhosis and 2.9% in those without cirrhosis. 
Conclusions: Coexisting cirrhosis is an infrequent but challenging co-morbidity in patients 
with VTE. Most patients were treated with anticoagulation, with low rates of fatal PE, 








Patients with liver cirrhosis are at an increased risk for hemorrhagic complications due to: 1) 
the reduced synthesis of coagulation factors, 2) thrombocytopenia secondary to 
hypersplenism and reduced synthesis of thrombopoietin and 3) conditions such as 
esophageal varices and portal gastropathy.(1) However, it is now known that cirrhosis could 
also lead into a hypercoagulable state due to an increase in procoagulants (factor VIII) and 
reduction of natural anticoagulants (protein C, protein S, antithrombin).(2) Therefore, some 
patients with cirrhosis, particularly those with additional risk factors for thrombosis 
(surgery, immobilization, malignancy) may also be at increased  risk for venous 
thromboembolism (VTE) including deep venous thrombosis (DVT) and pulmonary embolism 
(PE).(1,3) 
Data about the clinical course and management of limb DVT and PE in patients with 
liver cirrhosis are limited,(4) and the natural history of these patients has not been clearly 
elucidated. There are no clear guidelines for treatment or monitoring the response to 
anticoagulant therapy in patients with cirrhosis, in part because it is a common exclusion 
criterion in randomized trials of antithrombotic therapy for VTE.(5) Real-world treatment 
patterns for these patients –in whom anticoagulant therapy decisions are complicated by 
the coexistence of coagulopathy and increased risk of bleeding–remain unknown. Further, 
although a recent study suggested higher 30-day mortality rates in VTE patients with 
coexisting cirrhosis compared with those without cirrhosis,(6) the study was based on 
discharge codes, with limited granular clinical information. Clinically important outcomes 
including bleeding events, VTE recurrences, and VTE-related mortality remain unknown in 
this population, as are longer-term outcomes. The absence of such information impacts 
future research and routine decision-making for cirrhotic patients with VTE.  
The Registro Informatizado de la Enfermedad TromboEmbolica (RIETE) registry is a 
large multinational registry of patients with VTE. Using the data from RIETE, we report the 
clinical presentation, treatment pattern and outcomes of patients with cirrhosis who 
4 
 
developed VTE. We compared the clinical presentation and outcomes in patients with and in 




Data Source and Study Protocol 
RIETE is a prospective multicenter international registry of consecutive patients with 
objectively-confirmed VTE. The methodology of the registry has been described elsewhere 
(ClinicalTrials.gov identifier: NCT02832245).(7) Briefly, RIETE includes 283 collaborating 
centers from 28 countries. The protocol for patient enrollment in RIETE has been approved 
by ethics committees at each of the participating enrolling centers. The study protocol for 




We included patients with biopsy-confirmed cirrhosis who developed a VTE event (limb DVT, 
PE, or both). Although RIETE has been initiated since March 2001, presence or absence of 
cirrhosis has been captured in the registry since February 2009. Therefore, in the current 
study, we considered eligible patients from 02/25/2009 to 08/06/2018. Patients with 
thrombosis at unusual sites (including isolated portal vein thrombosis) were excluded from 
the current study. The minimum duration of follow-up in RIETE is 3 months, although many 
patients may have 6-month, 1-year, or even more prolonged follow-up available. We 
compared the clinical presentation (including inpatient or outpatient status and presenting 
signs and symptoms), baseline co-morbidities and the laboratory data in those with VTE and 






Patients were managed according to the clinical practice of each participating hospital (i.e., 
there was no standardization of treatment). We reported the type of VTE therapies used for 
patients, including whether not anticoagulation was used. In those receiving anticoagulants, 
we determined the type and duration of anticoagulation. We also assessed the use of 
thrombolytic therapy and inferior vena caval (IVC) filters. 
 
Outcomes 
The primary outcome was 30-day all-cause mortality. Other outcome measures included 30-
day fatal bleeding, 30-day PE-related mortality, and similar outcomes at 90-day and 1-year 
follow-up. Bleeding was considered as major, according to RIETE definition, if it was overt 
and required a transfusion ≥2 units of blood, involved a critical site (retroperitoneal, spinal 
or intracranial), or was fatal.(7) We also explored non-major bleeding events. We compared 
the index VTE presentation, patterns of therapy, and outcomes in patients with VTE and 
cirrhosis, compared with VTE patients who did not have cirrhosis.  
 
Statistical Analysis 
Continuous data were reported as mean and standard error of the mean (or median and 
interquartile range [IQR], where appropriate) and compared using t-test (or its non-
parametric counterpart, where needed). Categorical variables were reported as frequencies 
and percentages and compared using a Chi squared test. We used multivariable adjustment 
using a Cox proportional hazard model for assessment of outcomes in VTE patients with 
versus those without cirrhosis. For all a priori defined analyses, we considered a two-sided 






Between February 25 2009 and August 6, 2018, there were 43,611 patients with VTE in 
RIETE, of whom 187 (0.43%) had biopsy-confirmed diagnosis of cirrhosis. Of those 187 
patients, 99 presented with DVT, 69 had PE and 19 had both DVT and PE. In patients with 
cirrhosis and VTE, compared with the rest of patients in RIETE, there was a greater 
proportion of men (66% versus 49%, P<0.001), diabetes (29% versus 15%, P<0.001), 
chronic heart failure (12% versus 7.2%, P<0.001) or active cancer (40% versus 23%, 
P<0.001) (Table 1). As expected, they had a higher relative frequency of gastroduodenal 
ulcer (11% versus 1.6%, P<0.001) and esophageal varices (17% versus 0.0.4%, P<0.001) 
and had lower mean hemoglobin values and platelet counts (12±2.4 versus 13±3.2; and 
170.4±109.1 versus 235.2±96.9; P<0.001 respectively for both comparisons). 
 
Treatment 
Overall, 3 of the 187 (1.6%) patients with cirrhosis and VTE were never started on 
anticoagulation, compared with 198 (0.46%) of VTE patients without cirrhosis (P=0.056). In 
the remaining 184 (98.4%) who received anticoagulation, the median duration of treatment 
was 109 days (IQR: 43-201 days). Enoxaparin was the most commonly used agent (median 
dose: 177 IU/Kg/day [IQR: 138-200 IU/Kg/day]). No patient with cirrhosis underwent 
thrombolytic therapy, while 10 (5.3%) patients received an inferior vena caval filter (Table 
2). In the rest of the RIETE cohort (i.e. those without cirrhosis), the median total duration of 
anticoagulation in those who received anticoagulants was 181 days (IQR: 101-323 days). 
Enoxaparin was the most commonly used agent for initial therapy (median dose: 188 
IU/Kg/day [IQR: 160-200 IU/Kg/day). 
 
Outcomes 
By the end of 30 days of follow-up, 20 (11%) patients with cirrhosis and VTE died, including 
4 (2.1%) with fatal bleeding events and 1 (0.53%) with PE-related death. Respective 
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numbers were 1,472 (3.4%) total deaths (P<0.001), 68 (0.16%) fatal bleeds, and 198 
(0.46%) PE-related deaths (P=0.57), in the rest of the cohort. All-cause mortality and fatal 
bleeding were similarly more frequent in patients with cirrhosis at 90-day follow-up (Table 
3). 
The 1-year cumulative incidence of all-cause mortality and fatal bleeding were higher 
in those with cirrhosis, compared with patients without cirrhosis (32.4% versus 11.3%, 
P=xx for Log-rank test; and 3.2% versus 0.5%, P=xx for Log-rank test, respectively). The 
1-year cumulative incidence of PE-related mortality was 0.6% in those with cirrhosis and 
0.5% in those without cirrhosis. 
The 1-year cumulative incidence of VTE recurrence was 8.5% in patients with 
cirrhosis and 2.9% in those without cirrhosis (P=xx for Log-rank test; Figure 2A). In 
addition, the 1-year cumulative incidence of major or clinically-relevant non-major bleeding 
was 16.4% in patients with cirrhosis, compared with 7.6% in those without cirrhosis (P=xx 





In a large multinational registry of patients with VTE, we noted that a minority (0.43%) had 
cirrhosis. Most of these patients with cirrhosis and VTE were treated with anticoagulation. 
However, they faced with increased recurrent thrombotic event rates and hemorrhagic 
events (including fatal bleeds), compared with the rest of RIETE enrollees. Nearly a third of 
these patients died by the end of 1-year follow up.  
The net clinical benefit of conventional antithrombotic treatment for VTE in patients 
with cirrhosis is uncertain. Although fatal PE occurred in only 1 patient with VTE and 
cirrhosis, non-fatal recurrent VTE was not uncommon (1-year cumulative incidence: 8.5%). 
Simultaneously, 1-year cumulative incidence of clinically relevant bleeding was as high as 
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16.4%, including 5 fatal bleeding events (4 of which occurred early in the course of 
anticoagulation). These findings are concerning and deserve further attention by 
hepatologists and thrombosis specialists. 
 There are many challenges to management of VTE in patients with cirrhosis. Patients 
with cirrhosis have been historically excluded from randomized trials of antithrombotic 
therapy randomized trials. Monitoring of international normalized ratio (INR) is also 
problematic in these patients because of underlying hepatic synthetic dysfunction. In our 
study, most of the participants received low-molecular weight heparins (at relatively similar 
daily doses compared with patients without cirrhosis) for the initial and the continued 
treatment of VTE. Although such therapy was associated with low rate of fatal PE, bleeding 
events were common, and indicate an unmet need for improvement. As such, alternative 
antithrombotic agents may need to be considered for patients with VTE and cirrhosis, such 
as the non–vitamin K antagonist oral anticoagulants (NOACs).  
It should be considered that advanced liver disease may reduce plasma albumin 
concentration, thereby affecting the protein-bound moiety of medications such as apixaban 
and rivaroxaban [ref]. Appropriate doses would still need to be defined. 
Few other studies have explored the presentation and outcomes of patients with 
cirrhosis who developed VTE. In a recent investigation based on administrative codes, 
Søgaard et al reported markedly lower rates of use of anticoagulation, but remarkably 
higher rates of all-cause 30-day mortality, compared with our study (including 35% 
mortality rate in PE patients with cirrhosis, and 16% in those without cirrhosis).(6)   
 
Limitations 
Our study has several limitations. First, we included patients with biopsy-confirmed 
cirrhosis. In this sense, caution should be exercised in generalizing the findings to cirrhotic 
patients who are diagnosed with other modalities. RIETE does not include detailed 
information about liver cirrhosis (including the etiology), or non-thrombotic complications. 
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As such, we were unable to report on factors such as bilirubin level, ascites, the markers of 
disease severity such as the MELD score, the Child Pugh score, or other cirrhosis-related 
non-hemorrhagic complications. However, the mortality rates that we observed were fairly 
similar to that of large groups of patients with cirrhosis studied in other investigations.(8) 
Further, RIETE includes accurate information about major therapies and outcomes, including 
the type of antithrombotic therapies, as well as thrombotic and hemorrhagic outcomes. 
Second, portal vein thrombosis is a distinct complication in patients with liver cirrhosis. 
Since RIETE does not specifically focus on detailed information related to patients with 
cirrhosis, we focused on cases of DVT and PE in this manuscript but did not investigate 
patients with portal vein thrombosis. Third, as a prospective registry, there are limitations in 
ascertaining the treatment effects, compared with randomized trials. Conducing a 
randomized trial in this patient population faces ethical and practical challenges. We hope 
our results, based on extensive patient-level data with multivariable adjustment for several 
potential confounders, provide helpful information for clinicians and investigators, until a 
randomized trial could be planned in future. 
 
In conclusion, in our study of patients with cirrhosis and VTE, most patients were 
treated with low-molecular weight heparins, had a low rate of fatal PE, but notable 
cumulative incidence of non-fatal recurrent VTE. However, bleeding events, including fatal 
bleeds, were common and many occurred during the first month of therapy. Future studies 
are required to determine if a modified treatment strategy may help manage the thrombotic 
risk while not dramatically heightening the hemorrhagic risks, thereby improving the 





We express our gratitude to Sanofi Spain for supporting this Registry with an unrestricted educational grant. We also express 
our gratitude to Bayer Pharma AG for supporting this Registry. Bayer Pharma AG’s support was limited to the part of RIETE 
outside Spain, which accounts for a xxx% of the total patients included in the RIETE Registry. We also thank the RIETE Registry 
Coordinating Center, S&H Medical Science Service, for their quality control data, logistic and administrative support. Dr. Bikdeli 
reports that he serves as an expert (on behalf of the plaintiff) for litigation related to inferior vena caval filters. The content of 
the current manuscript is not directly related to that litigation. Dr. Bikdeli was supported by the National Heart, Lung, and Blood 
Institute, National Institutes of Health, through grant number T32 HL007854. The content is solely the responsibility of the 
authors and does not necessarily represent the official views of the NIH. 
 








































Table1. Demographics, Co-morbidities, and Basic Laboratory Findings 
 Patients with VTE and 
Cirrhosis         N (%) 
N=187 
Patients with VTE but 
without Cirrhosis        N (%) 
N=43,424 
P-Value 
VTE Presentation    
DVT Only 99 (53%) 19,424 (45%) 0.027 
PE Only 69 (37%) 16,588 (38%) 0.761 
Both DVT and PE 19 (10%) 7,412 (17%) 0.013 
Demographics    
Male (%) 124 (66%) 21,106 (49%) <0.001 
Age (years ± SD) 67.3±11.2 65.1±17.8 0.008 
Body mass index (kg/m2) 27±5 28±5.6 0.035 
Inpatient status  65 (35%) 12,351 (30%) 0.104 
Co-morbidities    
Diabetes 55 (29%) 6,404 (15%) <0.001 
Heart Failure 22 (12%) 3,117 (7.2%) 0.022 
Prior vascular disease 
(coronary or peripheral) 
15 (8.0%) 3,021 (7.0%) 0.563 
Prior stroke 10 (5.3%) 2,768 (6.4%) 0.654 
Chronic Lung Disease 28 (15%) 5,223 (12%) 0.214 
Active Cancer 75 (40%) 10,015 (23%) <0.001 
Major bleeding within the 
past 30 days 
8 (4.3%) 987 (2.3%) 0.079 
Recent Surgery 21 (11%) 4,742 (11%) 0.918 
Prior VTE 29 (16%) 6,506 (15%) 0.847 
Gastroduodenal ulcer 21 (11%) 699 (1.6%) <0.001 
Esophageal varices 31 (17%) 19 (0.04%) <0.001 
Laboratory Tests    
Hemoglobin (gr/dl) 12±2.4 13±3.2 0.000 
Platelet count 170.4±109.1 235.2±96.9 0.000 
Plasma creatinine (gr/dl) 1.1±1.1 1±0.6 0.314 
Background Therapies    
Non-steroidal anti-
inflammatory agents 
7 (3.7%) 2,882 (6.6%) 0.138 
Antiplatelet agents 28 (15%) 7,316 (17%) 0.552 
Corticosteroids 18 (9.6%) 3,974 (9.2%) 0.813 
DVT: deep vein thrombosis; INR: international normalizd ratio; PE: pulmonary embolism; RIETE: Registro 





Table 2. Initial Treatment  
 Patients with VTE and 
Cirrhosis         N (%) 
Patients with VTE but 
without Cirrhosis        N (%) 
P-Value 
No anticoagulation at all 3 (1.6%) 198 (0.46%) 0.056 
Anticoagulation Regimen in Those Who Received Anticoagulation 
Duration of anticoagulation  109 days (IQR: 43-201) 181 days (IQR: 101-323)  
Median  daily enoxaparin dose per Kg 
of body weight (for initial therapy) 
177 IU/Kg/day (138-200) 188 IU/Kg/day (160-200)  
Thrombolytic therapy 0 671 (1.5%) 0.125 
Vena caval filter 10 (5.3%) 1,160 (2.7%) 0.036 
    
Outcomes    
 
30-day Outcomes 
   
30-day fatal bleeding 4 (2.1%) 68 (0.16%) <0.001 
30-day fatal gastrointestinal bleeding  1 (0.53%) 21 (0.05%) 0.090 
30-day major bleeding (fatal or non-
fatal) 
16 (8.6%) 1,178 (2.7%) <0.001 
30-day major gastrointestinal bleeding 
(fatal or non-fatal)  
4 (2.1%) 306 (0.70%) 0.045 
30-day RIETE non-fatal major bleeding 5 (2.7%) 445 (1.0%) 0.045 
30-day clinically-relevant non-major 
bleeding 
7 (3.7%) 643 (1.5%)* 0.023 
30-day clinically-relevant non-major 
gastrointestinal bleeding  
1 (0.53%) 143 (0.33%) 0.462 
30-day non-fatal VTE 1 (0.53%) 272 (0.63%) 1.000 
30-day PE-related mortality 1 (0.53%) 198 (0.46%) 0.576 
30-day all-cause mortality 20 (11%) 1,472 (3.4%) <0.001 
 
90-day Outcomes 
90-day fatal bleeding 5 (2.7%) 98 (0.23%) <0.001 
90-day fatal gastrointestinal bleeding  1 (0.53%) 26 (0.06%) 0.110 
90-day major bleeding (fatal or non-
fatal) 
23 (12%) 1,768 (4.1%) <0.001 
90-day gastrointestinal major bleeding 
(fatal or non-fatal)  
8 (4.3%) 476 (1.1%) 0.001 
90-day RIETE non-fatal major bleeding 10 (5.3%) 585 (1.3%) <0.001 
90-day clinically-relevant non-major 
bleeding 
8 (4.3%) 1,037 (2.4%) 0.093 
90-day clinically-relevant 
gastrointestinal non-major bleeding  
2 (1.1%) 231 (0.53%) 0.264 
90-day non-fatal VTE 4 (2.1%) 463 (1.1%) 0.142 
90-day PE-related mortality 1 (0.53%) 216 (0.50%) 0.607 
90-day all-cause mortality 34 (18%) 2,677 (6.2%) <0.001 






















1-year fatal bleeding 5 (2.7%) 150 (0.35%) <0.001 
1-year fatal gastointestinal bleeding  1 (0.53%) 40 (0.09%) 0.162 
1-year major bleeding (fatal or non-
fatal) 
25 (13%) 2,469 (5.7%) <0.001 
1-year major gastrointestinal bleeding 
(fatal or non-fatal)  
9 (4.8%) 704 (1.6%) 0.004 
1-year RIETE non-fatal major bleeding 12 (6.4%) 747 (1.7%) <0.001 
1-year clinically-relevant non-major 
bleeding 
8 (4.3%) 1,505 (3.5%) 0.543 
1-year clinically-relevant 
gastrointestinal non-major bleeding  
2 (1.1%) 364 (0.84%) 0.672 
1-year non-fatal VTE 5 (2.7%) 673 (1.5%) 0.221 
1-year PE-related mortality 1 (0.53%) 224 (0.52%) 0.621 
1-year all-cause mortality 43 (23%) 3,775 (8.7%) <0.001 
DVT: deep vein thrombosis, IU: international units, LMWH: low-molecular-weight heparin, NOACs: Non-vitamin K oral 
anticoagulants, PE: pulmonary embolism, SD: standard deviation, VTE: venous thromboembolism 
17 
 
Table 3. Outcomes in Patients with Cirrhosis Compared with Those without Cirrhosis 
 Patients with VTE and 
Cirrhosis         N (%) 
Patients with VTE but 
without Cirrhosis        N (%) 
P-Value 
30-day Outcomes    
30-day fatal bleeding 4 (2.1%) 68 (0.16%) <0.001 
30-day fatal gastrointestinal bleeding  1 (0.53%) 21 (0.05%) 0.090 
30-day major bleeding (fatal or non-
fatal) 
16 (8.6%) 1,178 (2.7%) <0.001 
30-day major gastrointestinal bleeding 
(fatal or non-fatal)  
4 (2.1%) 306 (0.70%) 0.045 
30-day RIETE non-fatal major bleeding 5 (2.7%) 445 (1.0%) 0.045 
30-day clinically-relevant non-major 
bleeding 
7 (3.7%) 643 (1.5%)* 0.023 
30-day clinically-relevant non-major 
gastrointestinal bleeding  
1 (0.53%) 143 (0.33%) 0.462 
30-day non-fatal VTE 1 (0.53%) 272 (0.63%) 1.000 
30-day PE-related mortality 1 (0.53%) 198 (0.46%) 0.576 
30-day all-cause mortality 20 (11%) 1,472 (3.4%) <0.001 
90-day Outcomes 
90-day fatal bleeding 5 (2.7%) 98 (0.23%) <0.001 
90-day fatal gastrointestinal bleeding  1 (0.53%) 26 (0.06%) 0.110 
90-day major bleeding (fatal or non-
fatal) 
23 (12%) 1,768 (4.1%) <0.001 
90-day gastrointestinal major bleeding 
(fatal or non-fatal)  
8 (4.3%) 476 (1.1%) 0.001 
90-day RIETE non-fatal major bleeding 10 (5.3%) 585 (1.3%) <0.001 
90-day clinically-relevant non-major 
bleeding 
8 (4.3%) 1,037 (2.4%) 0.093 
90-day clinically-relevant 
gastrointestinal non-major bleeding  
2 (1.1%) 231 (0.53%) 0.264 
90-day non-fatal VTE 4 (2.1%) 463 (1.1%) 0.142 
90-day PE-related mortality 1 (0.53%) 216 (0.50%) 0.607 
90-day all-cause mortality 34 (18%) 2,677 (6.2%) <0.001 
1-year Outcomes    
1-year fatal bleeding 5 (2.7%) 150 (0.35%) <0.001 
1-year fatal gastrointestinal bleeding  1 (0.53%) 40 (0.09%) 0.162 
1-year major bleeding (fatal or non-
fatal) 
25 (13%) 2,469 (5.7%) <0.001 
1-year major gastrointestinal bleeding 
(fatal or non-fatal)  
9 (4.8%) 704 (1.6%) 0.004 
1-year RIETE non-fatal major bleeding 12 (6.4%) 747 (1.7%) <0.001 
1-year clinically-relevant non-major 
bleeding 





gastrointestinal non-major bleeding  
2 (1.1%) 364 (0.84%) 0.672 
1-year non-fatal VTE 5 (2.7%) 673 (1.5%) 0.221 
1-year PE-related mortality 1 (0.53%) 224 (0.52%) 0.621 
1-year all-cause mortality 43 (23%) 3,775 (8.7%) <0.001 
DVT: deep vein thrombosis, IU: international units, LMWH: low-molecular-weight heparin, NOACs: Non-vitamin K oral 
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